Reference: Release No. 2026-28
Official publication: Read the full Release No. 2026-28 on the agency website
On March 16, 2026, the Securities and Exchange Commission issued Release No. 2026-28 proposing amendments to Exchange Act Rule 15c2-11. The proposal is narrow in text but significant in effect: it would revise Rule 15c2-11 so that the rule refers only to equity securities, a change the Commission framed as clarifying the rule’s proper asset-class scope for broker-dealers that publish quotations or maintain a continuous quoted market in over-the-counter securities.
Executive Summary
The SEC describes Rule 15c2-11 as a long-standing anti-fraud and anti-manipulation measure for OTC markets. In Release No. 2026-28, the Commission proposes to amend the rule so that it expressly applies only to equity securities. The agency’s public statement indicates that the proposal is intended to confirm what the SEC characterizes as the historical understanding of the rule while tailoring the regulatory text to the asset class at issue.
For attorneys, compliance officers, broker-dealers, market makers, and financial institutions with OTC exposure, the proposal matters for at least three reasons. First, it signals the SEC’s current interpretive and policy position regarding the proper reach of Rule 15c2-11. Second, it may affect supervisory, legal, and operational assumptions that institutions have adopted for non-equity instruments quoted in OTC markets. Third, it opens a 60-day comment window after Federal Register publication during which affected market participants should evaluate whether the proposed amendments align with current business models, risk controls, and documentation practices.
The proposal does not eliminate compliance risk in OTC markets. It instead sharpens the question of which products remain subject to Rule 15c2-11’s information review framework and which products may be governed through other rules, antifraud authorities, trading venue requirements, or firm-level supervisory obligations. Firms should avoid reading the proposal as a general reduction in regulatory scrutiny. The practical issue is rule calibration, not deregulation.
What the Regulator Issued
The SEC announced a proposed rulemaking concerning Exchange Act Rule 15c2-11, the rule that establishes certain information gathering and review requirements for broker-dealers before they publish quotations for securities in the OTC market or maintain a continuous quoted market. According to the SEC’s release, the rule has historically focused on preventing manipulative and fraudulent trading schemes in OTC equity markets.
Under the proposal, Rule 15c2-11 would be amended to refer only to equity securities. Chairman Paul S. Atkins stated that regulations should be appropriately tailored to the asset class to which they apply and that the proposal would clarify regulatory obligations when publishing quotations while affirming what was always understood: Rule 15c2-11 applies to equity securities.
The SEC also stated that the full proposing release is available on its website and will be published in the Federal Register, with a comment period remaining open for 60 days after Federal Register publication. The official press release is available here: SEC Release No. 2026-28.
At the public release stage, the most important legal point is that this is a proposal, not a final rule. Institutions should therefore distinguish between current binding obligations and possible future amendments. The proposing release may also contain rationale, definitional detail, transition discussion, and request-for-comment items that become central to later enforcement posture or examination expectations even before any final adoption.
Why It Matters
Rule 15c2-11 occupies a critical place in the OTC quotation framework because it governs when and how broker-dealers may quote securities in a market segment associated with reduced issuer transparency, lower liquidity, and heightened manipulation risk. Any change to the rule’s express scope can alter compliance architecture well beyond the text of the amendment itself.
For broker-dealers and institutions active in OTC markets, the proposal matters operationally. Firms often build surveillance, onboarding, product classification, and quoting workflows around assumptions about whether Rule 15c2-11 applies. If the final rule confirms that only equity securities fall within the rule’s text, firms will need to reassess how they classify instruments, document quotation eligibility, and allocate compliance resources among equities, debt, and other non-equity products traded or quoted OTC.
The proposal also matters from a governance perspective. Many firms have embedded Rule 15c2-11 concepts into written supervisory procedures, exception reports, legal review templates, and training materials in ways that may not cleanly distinguish among asset classes. A narrower textual scope could create gaps if institutions remove controls too aggressively, or friction if they retain outdated procedures that do not match the amended rule. In either case, compliance leaders should expect examination staff and internal audit teams to ask why the firm’s policy framework does or does not change.
Financial institutions should also view the proposal through a litigation and enforcement lens. Even if Rule 15c2-11 is clarified to apply only to equity securities, the SEC and FINRA retain broad antifraud, books-and-records, supervisory, and fair dealing authorities. A firm that treats the proposal as permission to relax diligence indiscriminately could create avoidable risk. The better reading is that the Commission is refining rule scope, not diminishing expectations for disciplined control environments.
Finally, the proposal matters strategically because comment opportunities in market-structure rulemakings can materially affect final regulatory text. Institutions with OTC businesses should consider whether the proposal leaves unresolved issues around definitions, mixed instruments, convertible products, quotation systems, legacy procedures, or implementation timing. If those issues matter, the comment process is the appropriate forum to create a record.
Practical Action Checklist
- Map product scope. Identify all OTC-quoted products across the enterprise and separate equity from non-equity instruments using a defensible legal taxonomy.
- Review quotation workflows. Determine where Rule 15c2-11 is coded into onboarding, approvals, surveillance, and exception management.
- Compare policies to current law. Confirm that written supervisory procedures reflect the rule as it exists today, not as it may be amended later.
- Flag non-equity dependencies. Identify controls that currently rely on Rule 15c2-11 concepts for debt or other instruments and decide whether those controls should remain for independent risk reasons.
- Update legal interpretations. Prepare an internal memorandum or governance note explaining the proposal, its non-final status, and any interim supervisory expectations.
- Evaluate comment participation. Consider whether the firm should submit a comment letter on asset-class definitions, implementation consequences, or interpretive clarity.
- Coordinate with business lines. Ensure trading, compliance, legal, operations, and technology teams use the same instrument classification logic.
- Preserve anti-fraud controls. Maintain diligence and surveillance measures appropriate to OTC market abuse risk regardless of the proposal’s narrowing language.
Open Questions and Watch Items
The public press release leaves several practical questions that firms should monitor in the proposing release and later comment record. One issue is definitional precision: how the SEC will treat instruments with equity-like features, such as convertibles or other hybrid structures, if quoted OTC. Another is operational implementation: whether the final release will include transition guidance for firms whose policies presently apply Rule 15c2-11 processes more broadly than the revised text would require.
Firms should also watch for the SEC’s explanation of historical practice. The Commission’s statement that the amendment would affirm what was always understood may influence how regulators and litigants frame past and future compliance expectations. That phrasing could become relevant when institutions assess remediation, supervisory calibration, or interpretive consistency across legacy files.
A further question is whether other regulators, self-regulatory organizations, or trading venues will respond by adjusting their own guidance or rulebooks. Even when an SEC rule narrows or clarifies scope, related market participants may continue to impose parallel requirements as a matter of access, risk management, or contractual standards.
My Law Tampa publishes this memorandum to assist attorneys, compliance officers, and financial institutions in evaluating the SEC’s proposed amendments to Rule 15c2-11 and their likely effects on OTC quotation compliance.
This memorandum is provided for informational purposes only, does not constitute legal advice, and does not create an attorney-client relationship with My Law Tampa.
Source Materials
- Official publication: Release No. 2026-28
- Regulator archive: SEC memo archive
- Memo library: browse the full regulatory memo archive
- Related memo: SEC Appoints David Woodcock as Director of the Division of Enforcement
- Related memo: SEC Memo: SEC Announces Enforcement Results for Fiscal Year 2025
- Related memo: SEC Memo: SEC Announces Agenda and Panelists for Roundtable on Options Market Structure
